The Jackson Laboratory completed its acquisition of the New York Stem Cell Foundation and held a launch event at NYSCF’s Manhattan facilities to mark the formation of a unified nonprofit research organization. JAX said the merger combines its mouse genetics and infrastructure with NYSCF’s automated stem‑cell platforms to accelerate translational work, citing the Baby KJ custom gene therapy story as a proof‑of‑concept for rapid, patient‑focused development. The union creates a multisite nonprofit research engine aimed at bridging genetics, stem cell automation and translational pipelines.